Summary

Eligibility
for people ages 18-75 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered Janus kinase 1 inhibitor, in adult participants with Crohn's Disease.

Official Title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Crohn's Disease Who Completed the Studies M14-431 or M14-433

Keywords

Crohn's Disease, Upadacitinib, ABT-494, Extension Study, Efficacy, Safety, Maintenance Study, Crohn Disease

Eligibility

Locations

  • UCSF Medical Center - Mount Zion /ID# 202372
    San Francisco California 94115 United States
  • Univ of California San Francis /ID# 164653
    San Francisco California 94158 United States
  • Care Access Research /ID# 167765
    San Pablo California 94806 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
Links
Related info
ID
NCT03345823
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 747 study participants
Last Updated